ORLANDO, Florida, Nov 10 (Reuters) - For long-term investors, the famous 'tortoise and the hare' fable is a useful reminder that the stock, sector or country racing ahead today may not be the winner tomorrow.This has been true of the performance of Chinese stocks vis-à-vis Wall Street at nearly every juncture over the past 30 years, perhaps surprisingly, given China's surge to global economic and financial powerhouse status in that time.With economic, trade, and geopolitical relations between the two superpowers at their lowest ebb in decades, investors are more attuned...
Nov 13 (Reuters) - Banks on the payment app Zelle have begun refunding victims of imposter scams to address consumer protection concerns raised by U.S. lawmakers and the federal consumer watchdog, in a major policy change.The 2,100 financial firms on Zelle, a peer-to-peer network owned by seven banks including JPMorgan Chase (JPM.N) and Bank of America (BAC.N), began reversing transfers as of June 30 for customers duped into sending money to scammers claiming to be from a government agency, bank or existing service provider, said Early Warning Services (EWS), the...
People walk past a booth of ICBC Credit Suisse Asset Management Co at the 2020 China International Fair for Trade in Services (CIFTIS), in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File photo Acquire Licensing RightsNEW YORK/LONDON, Nov 10 (Reuters) - Industrial and Commercial Bank of China injected capital into its U.S. unit to pay BNY Mellon (BK.N) $9 billion for unsettled trades and hired a cybersecurity firm to help it return online after a ransomware attack, sources familiar with the matter said.ICBC said on Thursday it had been hit by...
The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsLONDON/COPENHAGEN, Nov 10 (Reuters) - Obesity drug maker Novo Nordisk (NOVOb.CO) said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.Novo Nordisk has had phenomenal success with its anti-obesity drug, Wegovy, but has scrambled to address shortages that have forced it to limit the number of patients.The World Health...